China Medical System

867 · HKEX

Public Market Listing

867HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for China Medical System are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(9 total)
9Total Assets
5Approved
3Phase 3 / Filed
1Phase 1–2 / Early
12Diseases
Quick filter:
Showing 9 of 9 assets
Target & Modality
Approved
Acetylcholinesterase/nicotinic receptor (prodrug)Small molecule
Alzheimer's Disease
Approved
VEGF-AAntibody fragment
Age-Related Macular DegenerationDiabetic Macular Edema
Wet Age-Related Macular Degeneration
Ferric derisomaltose(Monoferric / Monofer)
Approved
Iron repletionOther
Heart FailureChronic Kidney DiseaseIron Deficiency Anemia
Approved
Dietary phosphateSmall molecule
Chronic Kidney DiseaseHyperphosphatemia
Approved
IL-23 p19Monoclonal antibody
Psoriatic ArthritisPsoriasis
Desidustat(Oxemia)
Phase 3
HIF prolyl hydroxylase (HIF-PH1/2/3)Small molecule
Chronic Kidney Disease
Phase 3
Adenosine A3 receptor
MASH / NASHHepatocellular Carcinoma
Phase 3
Adenosine A3 receptorSmall molecule
Psoriasis
Phase 2/3
TYK2Small molecule
Atopic DermatitisPsoriasis

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (5)
January 2027 (1)
CMS-D001Phase 2Moderate to Severe Atopic Dermatitis
Est. primary completion 2027-01-31 · NCT07465120 · CT.gov ↗
What to watch
April 2027 (1)
Ferric derisomaltose · Monoferric / MonoferPhase 3Iron Deficiency, Anaemia in Children
Est. primary completion 2027-04-30 · NCT05179226 · CT.gov ↗
What to watch
August 2027 (1)
PiclidenosonPhase 2Lowe Syndrome
Est. primary completion 2027-08-31 · NCT07410455 · CT.gov ↗
What to watch
December 2027 (2)
PiclidenosonPhase 3Plaque Psoriasis
Est. primary completion 2027-12 · NCT06643260 · CT.gov ↗
What to watch
Ferric derisomaltose · Monoferric / MonoferPhase 3Chronic Heart Failure, Iron Deficiencies
Est. primary completion 2027-12-01 · NCT06929806 · CT.gov ↗
What to watch
2028 (2)
February 2028 (1)
CMS-D001Phase 2/3Moderate to Severe Plaque Psoriasis
Est. primary completion 2028-02-29 · NCT07432854 · CT.gov ↗
What to watch
December 2028 (1)
tildrakizumab · IlumyaPhase 3Psoriatic Arthritis
Est. primary completion 2028-12 · NCT04991116 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

29 October 2026FDA action datetildrakizumabILUMYA psoriatic arthritis FDA action date October 29, 2026
US, FDA · Sun Pharmaceutical Industries · Source ↗
29 October 2026ApprovaltildrakizumabFDA approves ILUMYA in active psoriatic arthritis
US, FDA · Source ↗
30 April 2026Topline resultNamodenosonNamodenoson Phase 2a pancreatic cancer data announced
16 March 2026Filing acceptedtildrakizumabFDA accepts ILUMYA sBLA for psoriatic arthritis
US, FDA · Sun Pharmaceutical Industries · Source ↗
21 July 2025Topline resulttildrakizumabINSPIRE-1 and INSPIRE-2 Phase 3 met primary endpoint
Sun Pharmaceutical Industries · Source ↗

Financial reports

Annual history (1 year)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$1.1B$81M——report ↗